# IZALCO (NCT05704049)

> A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05704049
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sanofi
- Conditions: Relapsed/Refractory Multiple Myeloma
- Interventions: Isatuximab; Carfilzomib; Dexamethasone; Dexamethasone IV; Montelukast; Acetaminophen; Diphenhydramine; Methylprednisolone
- Enrollment: 118
- Primary outcome: Overall response rate (ORR) - Cohorts 1 to 3
- Primary outcome: Maximum observed concentration (Cmax) over Cycle 1- Cohorts 4 to 5
- Primary outcome: Cumulative area under the curve over the first 4 weeks (AUC4weeks) of isatuximab treatment- Cohorts 4 to 5

## Commentary we found

- YouTube: 15
- Podcasts: 12
- X threads: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=izalco-nct05704049

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05704049", "email": "<work email>"}; the inbox owner confirms by the emailed link.